Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Yselty, linzagolix choline, Date of authorisation: 14/06/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Yselty, linzagolix choline, Date of authorisation: 14/06/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Rekambys, rilpivirine, Date of authorisation: 17/12/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Rekambys, rilpivirine, Date of authorisation: 17/12/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Gencebok, caffeine citrate, Date of authorisation: 19/08/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Gencebok, caffeine citrate, Date of authorisation: 19/08/2020, Revision: 8, Status: Authorised

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 21 January 2025, 09:30 (CET) to 21 January 2025, 13:00 (CET)

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 21 January 2025, 09:30 (CET) to 21 January 2025, 13:00 (CET)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness